unknown
Stage
About
Amplo Biotechnology develops AAV gene therapies targeting diseases of the neuromuscular junction, including Congenital Myasthenic Syndromes and muscular dystrophies, with their lead candidates AMP-101 and AMP-201 in preclinical and clinical trial preparation stages.
Explore Amplo Biotechnology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.